围手术期不停用抗血小板药物在单节段腰椎管狭窄症和腰椎间盘摘除微创减压手术中的安全性:无选择偏倚研究
本研究回顾性纳入2018年4月至2022年12月在本院因腰椎管狭窄症或腰椎间盘突出症行单节段微创减压手术的303例患者,其中41例围手术期继续抗血小板治疗。经倾向性评分匹配后,两组在硬膜外血肿再手术率、硬膜外血肿体积、红细胞计数差值、血红蛋白差值、血细胞比容差值及围手术期血栓栓塞并发症发生率方面均无显著差异。结论认为围手术期继续抗血小板治疗对单节段腰椎微创减压手术是安全的。
要点
- 围手术期继续抗血小板治疗不增加单节段腰椎微创减压术后硬膜外血肿再手术风险。
- 继续抗血小板组与对照组的硬膜外血肿体积及血液学指标变化无显著差异。
- 围手术期血栓栓塞并发症发生率在两组间无显著差异。
核心结论
- 围手术期继续抗血小板治疗对单节段腰椎微创减压手术是安全的,即使不存在选择偏倚。
研究设计与样本
- 回顾性研究,纳入2018年4月至2022年12月在本院因腰椎管狭窄症和腰椎间盘突出症行单节段微创减压手术的患者303例,其中抗血小板继续组41例。
- 采用倾向性评分按1:1匹配以调整患者基线特征和既往病史。
主要发现
- 倾向性评分匹配后,硬膜外血肿再手术率、硬膜外血肿体积、红细胞计数差值、血红蛋白差值、血细胞比容差值及围手术期血栓栓塞并发症发生率在两组间均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Each institution or physician has to decide on an individual basis whether to continue or discontinue antiplatelet (AP) therapy before spinal surgery. The purpose of this study was to determine if perioperative AP continuation is safe during single-level microsurgical decompression (MSD) for treating lumbar spinal stenosis (LSS) and lumbar disc hernia (LDH) without selection bias. METHODS: Patients who underwent single-level MSD for LSS and LDH between April 2018 to December 2022 at our institute were included in this retrospective study. We collected data regarding baseline characteristics, medical history/comorbidities, epidural hematoma (EDH) volume, reoperation for EDH, differences between preoperative and one-day postoperative blood cell counts (ΔRBC), hemoglobin (ΔHGB), and hematocrits (ΔHCT), and perioperative thromboembolic complications. Patients were divided into two groups: the AP continuation group received AP treatment before surgery and the control group did not receive antiplatelet medication before surgery. Propensity scores for receiving AP agents were calculated, with one-to-one matching of estimated propensity scores to adjust for patient baseline characteristics and past histories. Reoperation for EDH, EDH volume, ΔRBC, ΔHGB, ΔHCT, and perioperative thromboembolic complications were compared between the groups. RESULTS: The 303 enrolled patients included 41 patients in the AP continuation group. After propensity score matching, the rate of reoperation for EDH, the EDH volume, ΔRBC, ΔHGB, ΔHCT, and perioperative thromboembolic complication rates were not significantly different between the groups. CONCLUSION: Perioperative AP continuation is safe for single-level lumbar MSD, even without biases.
引用
- Ikeda N, Yokoyama K, Ito Y, et al. The safety of perioperative antiplatelet continuation without selection biases in microsurgical decompression surgery for single level lumbar spinal stenosis and lumbar disc herniotomy. Acta Neurochir (Wien). 2024. PMID: 38864938. doi:10.1007/s00701-024-06156-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。